Structure-Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2024 Feb 5

PMID 38313530

Authors

Muhammad Naufal

Elvira Hermawati

Yana Maolana Syah

Ace Tatang Hidayat

Ika Wiani Hidayat

Jamaludin Al-Anshori

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the most prominent causes of the rapidly growing mortality numbers worldwide. Cancer originates from normal cells that have acquired the capability to alter their molecular, biochemical, and cellular traits. The alteration of cell signaling enzymes, such as kinases, can initiate and amplify cancer progression. As a curative method, the targeted therapy utilized small molecules' capability to inhibit kinase's cellular function. This review provides a brief history (1999-2023) of Small Molecule Kinase Inhibitors (SMKIs) discovery with their molecular perspective. Furthermore, this current review also addresses the application and the development of hydantoin, thiazolidinedione, and rhodanine-based derivatives as kinase inhibitors toward several subclasses (EGFR, PI3K, VEGFR, Pim, c-Met, CDK, IGFR, and ERK) accompanied by their structure-activity relationship study and their molecular interactions. The present work summarizes and compiles all the important structural information essential for developing hydantoin, thiazolidinedione, and rhodanine-based kinase inhibitors to improve their potency in the future.

Citing Articles

Identification of Furin Protease Small-Molecule Inhibitor with a 1,3-Thiazol-2-ylaminosulfonyl Scaffold.

Kolaric A, Ravnik V, Stumpf Horvat S, Jukic M, Bren U Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006084 PMC: 11859198. DOI: 10.3390/ph18020273.

Rapid and Environmentally-Friendly Synthesis of Thiazolidinone Analogues in Deep Eutectic Solvent Complemented with Computational Studies.

Kumar G, Seboletswe P, Gcabashe N, Dhawan S, Manhas N, Bhargava G ChemistryOpen. 2024; 14(2):e202400198.

PMID: 39460430 PMC: 11808275. DOI: 10.1002/open.202400198.

What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible....

Szupryczynski K, Czelen P, Jelinski T, Szefler B Int J Nanomedicine. 2024; 19:9503-9547.

PMID: 39296940 PMC: 11410046. DOI: 10.2147/IJN.S469217.

Green synthesis, modeling, and biological evaluation of -substituted ()-5-arylidene imidazolidine/thiazolidine-2,4-dione/4-thione derivatives catalyzed by Bu SOH core-shell nanostructures.

Akhavan M, Esam Z, Mirshafa A, Lotfi M, Pourmand S, Ashori F RSC Adv. 2024; 14(32):22916-22938.

PMID: 39035715 PMC: 11259107. DOI: 10.1039/d4ra03881a.

References

Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G . Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors. Bioorg Med Chem Lett. 2011; 21(8):2224-8. DOI: 10.1016/j.bmcl.2011.03.003. View

Okamoto K, Ikemori-Kawada M, Jestel A, von Konig K, Funahashi Y, Matsushima T . Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2015; 6(1):89-94. PMC: 4291723. DOI: 10.1021/ml500394m. View

Panigrahy D, Singer S, Shen L, Butterfield C, Freedman D, Chen E . PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002; 110(7):923-32. PMC: 151148. DOI: 10.1172/JCI15634. View

Liu X, Xie H, Luo C, Tong L, Wang Y, Peng T . Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening. J Med Chem. 2010; 53(6):2661-5. DOI: 10.1021/jm901798e. View

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C . Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012; 343(2):342-50. DOI: 10.1124/jpet.112.197756. View

Jung K, Samadani R, Chauhan J, Nevels K, Yap J, Zhang J . Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. Org Biomol Chem. 2013; 11(22):3706-32. PMC: 3663054. DOI: 10.1039/c3ob40199e. View

Schwartz P, Murray B . Protein kinase biochemistry and drug discovery. Bioorg Chem. 2011; 39(5-6):192-210. DOI: 10.1016/j.bioorg.2011.07.004. View

Amrhein J, Knapp S, Hanke T . Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. J Med Chem. 2021; 64(12):7991-8009. DOI: 10.1021/acs.jmedchem.1c00217. View

Alkahtani H, Alanazi M, Aleanizy F, Alqahtani F, Alhoshani A, Alanazi F . Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies. Saudi Pharm J. 2019; 27(5):682-693. PMC: 6598223. DOI: 10.1016/j.jsps.2019.04.003. View

10.

El-Adl K, El-Helby A, Sakr H, Ayyad R, Mahdy H, Nasser M . Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch Pharm (Weinheim). 2020; 354(2):e2000279. DOI: 10.1002/ardp.202000279. View

11.

Good A, Liu J, Hirth B, Asmussen G, Xiang Y, Biemann H . Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. J Med Chem. 2012; 55(6):2641-8. DOI: 10.1021/jm2014698. View

12.

Ito S, Otsuki S, Ohsawa H, Hirano A, Kazuno H, Yamashita S . Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use. ACS Med Chem Lett. 2023; 14(4):396-404. PMC: 10108393. DOI: 10.1021/acsmedchemlett.3c00006. View

13.

Sawaguchi Y, Yamazaki R, Nishiyama Y, Mae M, Abe A, Nishiyama H . Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities. Front Pharmacol. 2021; 12:672536. PMC: 8126654. DOI: 10.3389/fphar.2021.672536. View

14.

Lee J, Park J, Hong V . Synthesis and evaluation of 5-(3-(pyrazin-2-yl)benzylidene)thiazolidine-2,4-dione derivatives as pan-pim kinases inhibitors. Chem Pharm Bull (Tokyo). 2014; 62(9):906-14. DOI: 10.1248/cpb.c14-00325. View

15.

Qi B, Yang Y, He H, Yue X, Zhou Y, Zhou X . Identification of novel N-(2-aryl-1, 3-thiazolidin-4-one)-N-aryl ureas showing potent multi-tyrosine kinase inhibitory activities. Eur J Med Chem. 2018; 146:368-380. DOI: 10.1016/j.ejmech.2018.01.061. View

16.

Cohen P, Cross D, Janne P . Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021; 20(7):551-569. PMC: 8127496. DOI: 10.1038/s41573-021-00195-4. View

17.

Mudit M, Khanfar M, Muralidharan A, Thomas S, Shah G, Soest R . Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products. Bioorg Med Chem. 2009; 17(4):1731-8. DOI: 10.1016/j.bmc.2008.12.053. View

18.

El-Adl K, Sakr H, Nasser M, Alswah M, Shoman F . 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Arch Pharm (Weinheim). 2020; 353(9):e2000079. DOI: 10.1002/ardp.202000079. View

19.

Weisberg E, Manley P, Breitenstein W, Bruggen J, Cowan-Jacob S, Ray A . Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7(2):129-41. DOI: 10.1016/j.ccr.2005.01.007. View

20.

Parslow T, Roskoski Jr R . A Primer on BRIMR: Understanding the Rankings of NIH Support from the Blue Ridge Institute for Medical Research. Am J Pathol. 2021; 192(3):392-394. PMC: 8895421. DOI: 10.1016/j.ajpath.2021.12.004. View